Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Malignant Neoplasm × dabrafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 68 Neoplasms 25 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Carcinoma, Anaplastic 9 Thyroid Neoplasms 8 Glioma 8 Brain Neoplasms 8 Skin Neoplasms 6 Multiple Myeloma 6 Hematologic Neoplasms 5 Colorectal Neoplasms 4 Ameloblastoma 4 Thyroid Cancer, Papillary 3 Glioblastoma 3 Astrocytoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Ganglioneuroma 2 Ganglioglioma 2 Fever 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thrombocytosis 1 Solid Tumor 1

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡